Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661225 | 0.88 | HPGDS (0.38) | HCRTR1HCRTR2KDM4EALDH1A1POLB | |
| SCHEMBL932973 | 0.84 | PRCP (0.36) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL2363127 | 0.80 | HCRTR1 (0.41) | HCRTR1HCRTR2SCD5MAPT | |
| SCHEMBL27855003 | 0.80 | HCRTR1 (0.39) | HCRTR1HCRTR2SCD5KMT2A | |
| SCHEMBL3781488 | 0.80 | HCRTR1 (0.39) | HCRTR1HCRTR2SCD5KMT2A | |
| SCHEMBL2454437 | 0.79 | HCRTR1 (0.38) | HCRTR1HCRTR2SCD5KMT2A | |
| SCHEMBL933610 | 0.79 | PRCP (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL933675 | 0.78 | PRCP (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL3448741 | 0.77 | TP53 (0.39) | HCRTR1HCRTR2KMT2A | |
| SCHEMBL16499066 | 0.77 | GRM5 (0.36) | HCRTR1HCRTR2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | HCRTR1 4187/4885HCRTR2 4696/4885HSD11B1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.